Replies to post #203173 on Biotech Values

[DewDiligence]

Couldn't the case be made that BMY would be more likely to do IO combo deals that could be synergistic?

BMY was strongly committed to Opdivo-based combination regimens in first-line NSCLC, and they continue to be strongly committed. That's why I said that the CHECKPOINT-026 setback is essentially a timing issue for the development of such regimens.